X

Drug Profile

Topixantrone

Alternative Names: BBR 3576

Latest Information Update: 09 Mar 2010

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cell Therapeutics
Class Antineoplastics
Mechanism of Action DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Gastric cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

31 Aug 2005 Topixantrone is available for partnering (http://www.cticseattle.com)
07 Jan 2004 Novuspharma has merged with and into Cell Therapeutics
09 Oct 2003 Data presented at the 12th European Cancer Conference (ECCO-2003) have been added to the adverse events and pharmacokinetics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com